Literature DB >> 12393802

Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells.

Wen Yang1, John R Dunlap, Richard B Andrews, Ronald Wetzel.   

Abstract

A number of observations point to the aggregation of expanded polyglutamine [poly(Q)]-containing proteins as playing a central role in the etiology of Huntington's disease (HD) and other expanded CAG-repeat diseases. Transfected cell and transgenic animal models provide some of this support, but irrefutable data on the cytotoxicity of poly(Q) aggregates is lacking. This may be due in part to difficulties in observing all aggregated states in these models, and in part to the inability to conclusively rule out the role of monomeric states of the poly(Q) protein. To address these questions, we produced aggregates of simple poly(Q) peptides in vitro and introduced them to mammalian cells in culture. We find that Cos-7 and PC-12 cells in culture readily take up aggregates of chemically synthesized poly(Q) peptides. Simple poly(Q) aggregates are localized to the cytoplasm and have little impact on cell viability. Aggregates of poly(Q) peptides containing a nuclear localization signal, however, are localized to nuclei and lead to dramatic cell death. Amyloid fibrils of a non-poly(Q) peptide are non-toxic, whether localized to the cytoplasm or nucleus. Nuclear localization of an aggregate of a short, Q(20), poly(Q) peptide is just as toxic as that of a long poly(Q) peptide, supporting the notion that the influence of poly(Q) repeat length on disease risk and age of onset is at the level of aggregation efficiency. The results support a direct role for poly(Q) aggregates in HD-related neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12393802     DOI: 10.1093/hmg/11.23.2905

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  119 in total

Review 1.  Modifiers and mechanisms of multi-system polyglutamine neurodegenerative disorders: lessons from fly models.

Authors:  Moushami Mallik; Subhash C Lakhotia
Journal:  J Genet       Date:  2010-12       Impact factor: 1.166

2.  Polyglutamine fibrillogenesis: the pathway unfolds.

Authors:  Christopher A Ross; Michelle A Poirier; Erich E Wanker; Mario Amzel
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-30       Impact factor: 11.205

Review 3.  From Alzheimer to Huntington: why is a structural understanding so difficult?

Authors:  Piero Andrea Temussi; Laura Masino; Annalisa Pastore
Journal:  EMBO J       Date:  2003-02-03       Impact factor: 11.598

4.  Targeting expression of expanded polyglutamine proteins to the endoplasmic reticulum or mitochondria prevents their aggregation.

Authors:  Erwann Rousseau; Benjamin Dehay; Léa Ben-Haïem; Yvon Trottier; Michel Morange; Anne Bertolotti
Journal:  Proc Natl Acad Sci U S A       Date:  2004-06-21       Impact factor: 11.205

5.  A structural model of polyglutamine determined from a host-guest method combining experiments and landscape theory.

Authors:  John M Finke; Margaret S Cheung; José N Onuchic
Journal:  Biophys J       Date:  2004-09       Impact factor: 4.033

6.  Small-molecule conversion of toxic oligomers to nontoxic β-sheet-rich amyloid fibrils.

Authors:  Jan Bieschke; Martin Herbst; Thomas Wiglenda; Ralf P Friedrich; Annett Boeddrich; Franziska Schiele; Daniela Kleckers; Juan Miguel Lopez del Amo; Björn A Grüning; Qinwen Wang; Michael R Schmidt; Rudi Lurz; Roger Anwyl; Sigrid Schnoegl; Marcus Fändrich; Ronald F Frank; Bernd Reif; Stefan Günther; Dominic M Walsh; Erich E Wanker
Journal:  Nat Chem Biol       Date:  2011-11-20       Impact factor: 15.040

Review 7.  Yeast prions assembly and propagation: contributions of the prion and non-prion moieties and the nature of assemblies.

Authors:  Mehdi Kabani; Ronald Melki
Journal:  Prion       Date:  2011-10-01       Impact factor: 3.931

Review 8.  Physical chemistry of polyglutamine: intriguing tales of a monotonous sequence.

Authors:  Ronald Wetzel
Journal:  J Mol Biol       Date:  2012-01-27       Impact factor: 5.469

9.  Architecture of polyglutamine-containing fibrils from time-resolved fluorescence decay.

Authors:  Christoph Röthlein; Markus S Miettinen; Tejas Borwankar; Jörg Bürger; Thorsten Mielke; Michael U Kumke; Zoya Ignatova
Journal:  J Biol Chem       Date:  2014-08-04       Impact factor: 5.157

Review 10.  A novel therapeutic strategy for polyglutamine diseases by stabilizing aggregation-prone proteins with small molecules.

Authors:  Motomasa Tanaka; Yoko Machida; Nobuyuki Nukina
Journal:  J Mol Med (Berl)       Date:  2005-03-10       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.